Molecular biology of Barrett's cancer.
Oesophageal adenocarcinoma (OA) remains one of the more deadly forms of gastro-intestinal cancer with a mortality rate exceeding 90%. The incidence of OA remains unabated and has a reported fivefold increase since 1970 [Pera M, Cameron AJ, Trastek VF, Carpenter HA & Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104(2): 510-513]. Gastro-oesophageal reflux disease and its sequelae, Barrett's oesophagus, is one of the principle risk factors in the development of OA, with a 30-fold increased risk in Barrett's patients compared with the general population [Tytgat GNJ. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's-Esophagus) have any real value. Endoscopy 1995; 27(1): 19-26]. OA is thought to be a microcosm of evolution, developing sequentially along the metaplasia-dysplasia-adenocarcinoma sequence. Progression is attributed to a series of genetic and epigenetic events that ultimately allow for clonal selection of Barrett's cells via subversion of intrinsic control mechanisms regulating cellular proliferation and/or apoptosis. This review will describe the current suppositions of the mechanisms behind the selection and subsequent expansion of Barrett's clones, and focus on some of the principle hallmarks associated with this transition.
Atherfold
Paul A
PA
Department of Clinical Pharmacology of Oxford, Oxford OX2 6HE, UK. paul.atherfold@clinpharm.ox.ac.uk
Jankowski
Janusz A
JA
D000230:Adenocarcinoma / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D001471:Barrett Esophagus / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D001647:Bile Acids and Salts / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D004943:Esophagogastric Junction / Q000378:metabolism / Q000473:pathology; D005755:Gastrins / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000150:complications / Q000378:metabolism / Q000473:pathology; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008679:Metaplasia / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D015995:Prevalence
D001647:Bile Acids and Salts; D005755:Gastrins; D018836:Inflammation Mediators